Hannover, Germany, June 25, 2026 – The European Multicentre Bronchiectasis Audit and
Research Collaboration (EMBARC), the leading pan-European research network dedicated to
advancing the understanding and treatment of bronchiectasis, announced today at the World
Bronchiectasis Conference (WBC 2026), its intention to collaborate with Insmed Incorporated to
evaluate brensocatib 25 mg – an oral, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1) – over
three years in an open-label, single-arm, interventional study enrolling up to 3,000 patients with
bronchiectasis across the United Kingdom, Spain, Germany, Belgium, France, and Italy.
The study will be designed to deepen understanding of the long-term use of brensocatib and
whether it has the potential to modify the course of the disease. This research would expand upon
the current evidence that demonstrated brensocatib slows lung function decline, a measure
used to indicate slower disease progression. The intended study will also evaluate whether
earlier, upstream use of the therapy is effective in further slowing the progression of
bronchiectasis, with a plan to include well-validated endpoints, along with some novel
composite endpoints.

“Building on ASPEN trial data showing that brensocatib 25 mg reduced exacerbation frequency,
slowed lung function decline, and produced structural changes in the airways, this study through
the EMBARC network will allow us to ask an even more ambitious question: whether intervening
earlier in the disease course can do more than slow progression, but fundamentally alter its
trajectory,” said lead study investigator James Chalmers, MBChB, Ph.D., Rhodes Chair of
Experimental Therapeutics and Respiratory Physician, University of Oxford. “Over a three-year
horizon, we have a real opportunity to understand whether earlier use of brensocatib can not only
reduce the burden of exacerbations and slow disease progression, but even more profoundly,
change the natural course of the disease. That is the question at the heart of this study, and the
answer could help shape how we treat bronchiectasis in the future.”

Bronchiectasis is a serious, chronic, and progressive inflammatory lung disease characterized by
the permanent widening of the airways, leading to persistent bacterial infections, excessive
mucus production, and recurrent pulmonary exacerbations. These exacerbations are associated
with accelerated lung function decline and poor quality of life. Bronchiectasis affects
approximately 600,000 people across Europe, and millions of people globally.

“EMBARC is one of the world’s leading bronchiectasis research networks, and this collaboration
reflects our commitment to understanding how brensocatib can make the greatest possible
difference in patients’ lives,” said Martina Flammer, M.D., MBA, Chief Medical Officer, Insmed.
“As a recognized innovator in bronchiectasis, we are spearheading transformative research
together with EMBARC and distinguished clinical experts. Together with the scientific and patient
community, we are uniquely positioned to help shape clinical advancement – and by studying
brensocatib earlier in the disease course and over the longer term in a large, heterogeneous
population, we hope to give patients the best possible chance of preserving their lung health.”

About EMBARC 

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was
established in 2012 as a collaborative group within the Respiratory Infections Assembly of the
European Respiratory Society (ERS) with the objective of creating a European bronchiectasis
registry, harmonizing existing databases, and identifying opportunities to raise the profile of
bronchiectasis at an international level. EMBARC is a pan-European research network dedicated
to improving the understanding, diagnosis, and treatment of bronchiectasis. It brings together
leading clinicians and researchers from across Europe to conduct high-quality interventional
research and clinical trials in bronchiectasis.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first-
and best-in-class therapies to transform the lives of patients facing serious diseases. The
Company is advancing a diverse portfolio of approved and mid- to late-stage investigational
medicines—including two approved therapies to treat chronic, debilitating lung diseases—as
well as cutting-edge drug discovery focused on serving patient communities where the need is
greatest. Insmed’s commercial portfolio and clinical pipeline are organized around three
therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The
Company’s research engine is advancing a wide range of technologies and modalities, including
gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit
of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations
throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the
best employers in the biopharmaceutical industry, including spending five consecutive years as
the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn,
Instagram, YouTube, and X.

Media Contact
MC Services AG
Eva Bauer, Alexander Sälzer
Email: embarc@mc-services.eu
Phone: +49 89 210 228 0